BIIB - Biogen Inc Stock Price, Fair Value and News

195.06USD-1.67 (-0.85%)Market Closed as of 16 Apr 2024, 09:40 am ET

Market Summary

USD195.06-1.67

Market Closedas of 16 Apr 2024, 09:40 am

-0.85%

BIIB Stock Price

View Fullscreen

BIIB RSI Chart

BIIB Valuation

Market Cap

28.6B

Price/Earnings (Trailing)

24.63

Price/Sales (Trailing)

2.91

EV/EBITDA

16.84

Price/Free Cashflow

22.51

BIIB Price/Sales (Trailing)

BIIB Profitability

Operating Margin

94.45%

EBT Margin

13.18%

Return on Equity

7.85%

Return on Assets

4.33%

Free Cashflow Yield

4.44%

BIIB Fundamentals

BIIB Revenue

Revenue (TTM)

9.8B

Rev. Growth (Yr)

-6.2%

Rev. Growth (Qtr)

-5.69%

BIIB Earnings

Earnings (TTM)

1.2B

Earnings Growth (Yr)

-54.63%

Earnings Growth (Qtr)

466.67%

Breaking Down BIIB Revenue

52 Week Range

195.06319.76

(Low)(High)

Last 7 days

-4.0%

Last 30 days

-10.3%

Last 90 days

-20.1%

Trailing 12 Months

-31.7%

How does BIIB drawdown profile look like?

BIIB Financial Health

Current Ratio

Debt/Equity

0.46

Debt/Cashflow

0.23

BIIB Investor Care

Shares Dilution (1Y)

0.61%

Diluted EPS (TTM)

7.98

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	10.1B	10.0B	10.0B	9.8B
2022	10.8B	10.6B	10.4B	10.2B
2021	12.6B	11.7B	11.1B	11.0B
2020	14.4B	14.5B	14.3B	13.4B
2019	13.8B	14.1B	14.2B	14.4B
2018	12.6B	12.9B	13.2B	13.5B
2017	11.5B	11.7B	11.8B	12.3B
2016	10.9B	11.2B	11.4B	11.4B
2015	10.1B	10.3B	10.6B	10.8B
2014	7.6B	8.3B	9.0B	9.7B
2013	5.6B	5.9B	6.4B	6.9B
2012	5.1B	5.3B	5.4B	5.5B
2011	4.8B	4.8B	4.9B	5.0B
2010	4.4B	4.6B	4.6B	4.7B
2009	4.2B	4.3B	4.3B	4.4B
2008	0	3.5B	3.8B	4.1B
2007	0	0	0	3.2B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Biogen Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 02, 2024	singhal priya	sold	-19,817	213	-93.00	head of development
Apr 01, 2024	murphy nicole	acquired	-	-	240	head of pharm ops and tech
Apr 01, 2024	murphy nicole	sold (taxes)	-25,135	214	-117	head of pharm ops and tech
Feb 22, 2024	singhal priya	sold	-57,962	221	-262	head of development
Feb 16, 2024	gregory ginger	acquired	-	-	4,704	evp, human resources
Feb 16, 2024	alexander susan h	acquired	-	-	5,037	evp chief legal officer
Feb 16, 2024	murphy nicole	sold (taxes)	-133,639	219	-610	head of pharm ops and tech
Feb 16, 2024	izzar rachid	acquired	-	-	2,017	head of global product strat.
Feb 16, 2024	izzar rachid	sold (taxes)	-208,564	219	-952	head of global product strat.
Feb 16, 2024	mcdonnell michael r	acquired	-	-	6,720	evp, chief financial officer

Which funds bought or sold BIIB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	ARGA Investment Management, LP	unchanged	-	-113,113	565,382	0.02%
Apr 12, 2024	HARBOR INVESTMENT ADVISORY, LLC	added	36.71	2,845	23,288	-%
Apr 12, 2024	Dynamic Advisor Solutions LLC	reduced	-72.56	-963,714	287,004	0.01%
Apr 12, 2024	ARMSTRONG ADVISORY GROUP, INC	unchanged	-	-	92,123	0.01%
Apr 12, 2024	AdvisorNet Financial, Inc	reduced	-52.00	-7,764	5,175	-%
Apr 12, 2024	GATEWAY INVESTMENT ADVISERS LLC	reduced	-11.73	-3,211,990	8,934,410	0.10%
Apr 12, 2024	Unison Advisors LLC	unchanged	-	-219,064	1,094,970	0.11%
Apr 12, 2024	STEPH & CO	new	-	10,350	10,350	-%
Apr 12, 2024	Riverview Trust Co	new	-	20,054	20,054	0.01%
Apr 12, 2024	A. D. Beadell Investment Counsel, Inc.	unchanged	-	-42,000	209,000	0.18%

Are Funds Buying or Selling BIIB?

Are funds buying BIIB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BIIB

No. of Funds

Unveiling Biogen Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 12, 2024	primecap management co/ca/	11.22%	16,264,481	SC 13G/A
Feb 12, 2024	vanguard group inc	10.02%	14,521,342	SC 13G/A
Feb 12, 2024	vanguard group inc	9.94%	14,406,879	SC 13G/A
Jan 24, 2024	blackrock inc.	9.8%	14,246,320	SC 13G/A
Feb 09, 2023	primecap management co/ca/	10.9%	15,700,576	SC 13G/A
Feb 09, 2023	vanguard group inc	8.32%	11,976,623	SC 13G/A
Jan 24, 2023	blackrock inc.	9.9%	14,260,137	SC 13G/A
Mar 07, 2022	blackrock inc.	9.4%	13,736,954	SC 13G/A
Feb 10, 2022	primecap management co/ca/	10.73%	15,757,405	SC 13G/A
Feb 09, 2022	vanguard group inc	7.85%	11,537,299	SC 13G/A

Recent SEC filings of Biogen Inc

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	PRE 14A	PRE 14A
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 02, 2024	144	Notice of Insider Sale Intent
Feb 26, 2024	4	Insider Trading
Feb 22, 2024	144	Notice of Insider Sale Intent
Feb 21, 2024	4	Insider Trading
Feb 21, 2024	4	Insider Trading
Feb 21, 2024	4	Insider Trading
Feb 21, 2024	4	Insider Trading

Peers (Alternatives to Biogen Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	355.4B	85.2B	-6.73%	-11.03%	10.11	4.17	6.46%	95.94%
MRK	319.5B	60.1B	3.80%	9.39%	875.25	5.31	1.40%	-97.49%
PFE	146.3B	46.5B	-7.30%	-37.12%	-105.33	3.14	42.59%	-114.62%
AMGN	142.3B	28.2B	-1.26%	6.20%	21.18	5.05	7.09%	2.52%
GILD	84.4B	27.1B	-8.06%	-18.37%	14.9	3.11	-0.60%	23.36%
TEVA	14.8B	15.8B	-1.49%	59.59%	-25.72	0.93	6.17%	76.47%
MID-CAP
PRGO	4.1B	4.7B	-0.79%	-17.32%	-321.5	0.88	4.58%	90.97%
ALKS	4.0B	1.7B	-16.49%	-18.19%	11.28	2.41	49.61%	324.78%
BHC	3.2B	8.8B	-6.09%	15.35%	-5.33	0.36	7.79%	-163.11%
AMPH	2.0B	644.4M	-5.18%	-3.16%	14.27	3.05	29.14%	50.51%
SMALL-CAP
TLRY	1.4B	743.2M	4.05%	-24.05%	-3.96	1.87	24.65%	80.36%
TXMD	22.7M	70.0M	-17.92%	-45.58%	-2.21	0.38	-19.54%	-109.18%
ACRX	17.5M	-	-10.43%	48.74%	-0.95	0.22	2882.68%	-138.52%
AGRX	1.1M	19.6M	-33.33%	-94.84%	-0.07	0.05	80.00%	43.08%
ACOR	546.5K	117.6M	-96.45%	-95.94%	0	0	-0.79%	-283.60%

Biogen Inc News

Latest updates

Biogen Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-5.7%	2,386	2,530	2,456	2,463	2,544	2,509	2,589	2,532	2,734	2,779	2,775	2,694	2,853	3,376	3,682	3,534	3,671	3,600	3,617	3,490	3,526
Costs and Expenses	-21.6%	2,095	2,672	1,748	2,025	1,940	1,137	1,320	2,184	2,582	2,488	2,193	1,720	2,686	2,290	1,707	1,714	1,894	1,794	1,661	1,987	2,083
S&GA Expenses	-22.8%	609	788	548	605	633	563	573	635	788	654	637	595	806	573	555	570	665	555	588	568	591
EBITDA Margin	-10.5%	0.21*	0.23*	0.38*	0.44*	0.43*	0.40*	0.29*	0.22*	0.23*	0.21*	0.26*	0.36*	-	-	-	-	-	-	-	-	-
Interest Expenses	12.1%	72.00	64.00	49.00	63.00	55.00	60.00	66.00	66.00	66.00	66.00	56.00	65.00	56.00	56.00	66.00	44.00	46.00	46.00	48.00	48.00	49.00
Income Taxes	158.6%	43.00	-72.90	115	51.00	54.00	236	217	126	443	-25.90	-409	44.00	13.00	241	446	292	276	211	248	423	470
Earnings Before Taxes	306.5%	292	-141	708	438	604	1,371	1,270	347	405	291	582	467	353	958	2,038	1,699	1,728	1,779	1,759	1,860	1,415
EBT Margin	-18.1%	0.13*	0.16*	0.31*	0.36*	0.35*	0.33*	0.22*	0.15*	0.16*	0.15*	0.20*	0.30*	-	-	-	-	-	-	-	-	-
Net Income	466.7%	250	-68.10	592	388	550	1,135	1,058	304	368	329	449	410	358	702	1,542	1,399	1,440	1,546	1,494	1,409	947
Net Income Margin	-19.3%	0.12*	0.15*	0.27*	0.31*	0.30*	0.28*	0.19*	0.13*	0.14*	0.14*	0.16*	0.24*	-	-	-	-	-	-	-	-	-
Free Cashflow	-110.2%	-52.70	518	416	389	-261	602	700	104	787	763	1,155	676	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-4.8%	26,845	28,193	25,157	24,598	24,554	24,854	25,081	23,614	23,877	23,807	24,470	23,855	24,619	24,934	25,512	26,119	27,234	27,484	26,288	26,446	25,289
Current Assets	-18.9%	6,859	8,454	10,432	9,763	9,791	9,766	9,741	7,916	7,857	7,162	7,184	6,720	6,887	7,843	8,494	8,007	8,382	8,448	7,910	8,943	7,641
Cash Equivalents	-54.1%	1,050	2,288	2,618	2,898	3,419	3,676	2,647	1,749	2,261	1,542	1,742	1,218	1,331	2,225	2,385	2,591	2,914	2,344	1,723	2,243	1,225
Inventory	-15.3%	2,527	2,982	1,334	1,281	1,344	1,375	1,294	1,215	1,352	1,348	1,255	1,172	1,069	1,028	953	859	804	752	777	770	930
Net PPE	0.2%	3,310	3,302	3,307	3,301	3,299	3,266	3,355	3,373	3,416	3,411	3,442	3,438	3,412	3,360	3,331	3,282	3,247	3,138	3,078	3,014	3,601
Goodwill	488.2%	6,219	1,057	5,754	5,752	5,749	5,741	5,750	5,758	5,761	5,761	5,764	5,763	5,762	5,756	5,751	5,752	5,758	5,746	5,749	5,640	5,706
Liabilities	-12.2%	12,045	13,714	10,696	10,811	11,166	12,087	13,218	12,394	12,918	12,925	13,256	13,192	13,933	14,190	14,223	13,582	13,895	13,492	13,339	12,624	12,257
Current Liabilities	-31.6%	3,434	5,022	3,187	3,015	3,273	3,926	5,018	3,947	4,298	4,212	3,347	3,166	3,742	3,804	3,447	4,639	4,864	4,432	3,211	3,149	3,295
Long Term Debt	-100.0%	-	6,786	6,285	6,283	6,281	6,279	6,277	6,276	6,274	6,272	7,269	7,267	7,426	7,425	7,424	4,460	4,459	4,458	5,949	5,943	5,937
Shareholder's Equity	2.2%	14,799	14,484	14,461	13,787	13,398	12,767	11,863	11,221	10,960	10,882	11,215	10,663	10,686	10,745	11,289	12,537	13,339	13,992	12,949	13,822	13,032
Retained Earnings	1.4%	17,628	17,378	17,446	16,854	16,467	15,916	14,960	14,216	13,912	13,544	13,901	13,834	13,976	13,961	14,467	15,673	16,455	17,065	16,183	17,027	16,257
Additional Paid-In Capital	24.9%	303	242	171	91.00	73.00	-	-	119	68.00	-	-	-	-	-	-	0.00	-	-	-	-	-
Shares Outstanding	0.1%	145	145	145	144	144	146	146	147	147	150	150	152	-	-	-	-	-	-	-	-	-
Minority Interest	100.0%	-	-4.10	-6.40	-9.60	-9.50	-8.70	-9.10	-21.60	64.00	452	463	-19.00	-14.20	-14.00	-19.50	-10.00	-4.10	-4.10	-4.10	-7.90	-8.00
Float	-	-	-	41,191	-	-	-	29,398	-	-	-	51,265	-	-	-	42,103	-	-	-	43,010	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-97.9%	13.00	592	487	455	-175	661	737	162	838	805	1,227	769	-367	1,181	1,949	1,467	1,960	1,695	1,964	1,460	1,895
Share Based Compensation	395.1%	191	-64.80	-74.10	76.00	189	-65.70	-58.00	68.00	170	-57.60	-55.80	70.00	132	-35.40	-49.50	68.00	139	-47.80	-55.00	46.00	35.00
Cashflow From Investing	62.6%	-652	-1,742	-753	-953	-141	1,672	694	-648	-112	-233	-152	-64.70	-166	-52.40	-832	443	708	-365	-110	239	-1,625
Cashflow From Financing	-176.1%	-646	849	-9.80	-43.40	-7.40	-1,251	-471	-16.50	10.00	-746	-564	-785	-401	-1,312	-1,313	-2,245	-2,116	-689	-2,375	-679	-1,437
Buy Backs	-	-	-	-	-	-	250	500	-	-	750	450	600	400	1,250	2,809	2,220	2,093	718	2,402	656	1,353

BIIB Income Statement

2023-12-31

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues	$ 9,835.6	$ 10,173.4	$ 10,981.7
Cost and expense:
Cost of sales, excluding amortization and impairment of acquired intangible assets	2,533.4	2,278.3	2,109.7
Research and development	2,462.0	2,231.1	2,501.2
Selling, general and administrative	2,549.7	2,403.6	2,674.3
Amortization and impairment of acquired intangible assets	240.6	365.9	881.3
Collaboration profit sharing/(loss reimbursement)	218.8	(7.4)	7.2
(Gain) loss on fair value remeasurement of contingent consideration	0.0	(209.1)	(50.7)
Acquired in-process research and development	0.0	0.0	18.0
Restructuring charges	218.8	131.1	0.0
Gain on sale of building	0.0	(503.7)	0.0
Other (income) expense, net	315.5	(108.2)	1,095.5
Total cost and expense	8,538.8	6,581.6	9,236.5
Income before income tax (benefit) expense and equity in loss of investee, net of tax	1,296.8	3,591.8	1,745.2
Income tax (benefit) expense	135.3	632.8	52.5
Equity in (income) loss of investee, net of tax	0.0	(2.6)	(34.9)
Net income	1,161.5	2,961.6	1,727.6
Net income (loss) attributable to noncontrolling interests, net of tax	0.4	(85.3)	171.5
Net income attributable to Biogen Inc.	$ 1,161.1	$ 3,046.9	$ 1,556.1
Net income per share:
Basic earnings per share attributable to Biogen Inc. (in dollars per share)	$ 8.02	$ 20.96	$ 10.44
Diluted earnings per share attributable to Biogen Inc. (in dollars per share)	$ 7.97	$ 20.87	$ 10.40
Weighted-average shares used in calculating:
Weighted average number of common shares outstanding (in shares)	144,700	145,300	149,100
Diluted earnings per share attributable to Biogen Inc. (in shares)	145,600	146,000	149,600
Product revenue, net
Revenues	$ 7,246.7	$ 7,987.8	$ 8,846.9
Revenue from anti-CD20 therapeutic programs
Revenues	1,689.6	1,700.5	1,658.5
Contract manufacturing, royalty and other revenue
Revenues	$ 899.3	$ 485.1	$ 476.3

BIIB Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 1,049.9	$ 3,419.3
Marketable securities	0.0	1,473.5
Accounts receivable, net of allowance for doubtful accounts of $2.4 and $2.3, respectively	1,664.1	1,705.0
Due from anti-CD20 therapeutic programs	435.9	431.4
Inventory	2,527.4	1,344.4
Other current assets	1,182.0	1,417.6
Total current assets	6,859.3	9,791.2
Marketable securities	0.0	705.7
Property, plant and equipment, net	3,309.7	3,298.6
Operating lease assets	420.0	403.9
Intangible assets, net	8,363.0	1,850.1
Goodwill	6,219.2	5,749.0
Deferred tax asset	928.6	1,226.4
Investments and other assets	745.0	1,529.2
Total assets	26,844.8	24,554.1
Current liabilities:
Current portion of term loan	150.0	0.0
Taxes payable	257.4	259.9
Accounts payable	403.3	491.5
Accrued expense and other	2,623.6	2,521.4
Total current liabilities	3,434.3	3,272.8
Notes payable and term loan	6,788.2	6,281.0
Deferred tax liability	641.8	334.7
Long-term operating lease liabilities	400.0	333.0
Other long-term liabilities	781.1	944.2
Total liabilities	12,045.4	11,165.7
Commitments, contingencies and guarantees (Notes 22 and 23)
Biogen Inc. shareholders’ equity
Preferred stock, par value $0.001 per share	0.0	0.0
Common stock, par value $0.0005 per share	0.1	0.1
Additional paid-in capital	302.5	73.3
Accumulated other comprehensive income (loss)	(153.7)	(164.9)
Retained earnings	17,627.6	16,466.5
Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively	(2,977.1)	(2,977.1)
Total Biogen Inc. shareholders’ equity	14,799.4	13,397.9
Noncontrolling interests	0.0	(9.5)
Total equity	14,799.4	13,388.4
Total liabilities and equity	$ 26,844.8	$ 24,554.1

About Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Christopher A. Viehbacher
WEBSITE	biogen.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	8725

Biogen Inc Frequently Asked Questions

What is the ticker symbol for Biogen Inc? What does BIIB stand for in stocks?

BIIB is the stock ticker symbol of Biogen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biogen Inc (BIIB)?

As of Mon Apr 15 2024, market cap of Biogen Inc is 28.6 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIIB stock?

You can check BIIB's fair value in chart for subscribers.

What is the fair value of BIIB stock?

You can check BIIB's fair value in chart for subscribers. The fair value of Biogen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biogen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BIIB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biogen Inc a good stock to buy?

The fair value guage provides a quick view whether BIIB is over valued or under valued. Whether Biogen Inc is cheap or expensive depends on the assumptions which impact Biogen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIIB.

What is Biogen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, BIIB's PE ratio (Price to Earnings) is 24.63 and Price to Sales (PS) ratio is 2.91. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIIB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Biogen Inc's stock?

In the past 10 years, Biogen Inc has provided -0.03 (multiply by 100 for percentage) rate of return.